Omslagafbeelding van de show Curie: The Oncology Brief

Curie: The Oncology Brief

Podcast door Curie: The Platform for HCPs

Engels

Technologie en Wetenschap

Tijdelijke aanbieding

2 maanden voor € 1

Daarna € 9,99 / maandElk moment opzegbaar.

  • 20 uur luisterboeken / maand
  • Podcasts die je alleen op Podimo hoort
  • Gratis podcasts
Begin hier

Over Curie: The Oncology Brief

Catch up quickly with The OncoBrief, your weekly digest of the top three oncology stories that matter most. Delivered clearly and concisely, we cover clinical breakthroughs, FDA approvals, and emerging trends keeping oncologists informed and ahead.

Alle afleveringen

20 afleveringen

aflevering Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC artwork

Radiation Oncology Consolidation, Neuropathy Prevention, and New Immunotherapy for HCC

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three key updates in oncology. A new analysis shows that radiation oncology practices are consolidating rapidly, raising concerns about access to care, patient choice, and job stability for oncologists. In breast cancer, a randomized trial finds that hand cooling and compression can significantly reduce chemotherapy-induced neuropathy, offering a simple, cost-effective strategy to protect patients’ nerves. And finally, the EMA has recommended expanding nivolumab plus ipilimumab for advanced hepatocellular carcinoma, positioning it as an alternative to the current standard of care. Tune in for the latest insights shaping cancer treatment.

21 mrt 2025 - 5 min
aflevering MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate artwork

MRD in AML, Early-Phase Cancer Trials Reality Check, and the Hospital-at-Home Debate

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three important topics shaping cancer care. A new study confirms that achieving MRD negativity early in AML is critical for long-term survival, reinforcing MRD’s growing role in treatment decisions. We then explore the hard truth about early-phase cancer trials, revealing that only 16.2% of phase 2 treatments ever gain FDA approval—what does this mean for patients enrolling in these studies? Finally, we examine the rapid expansion of Hospital-at-Home care, a model that could change oncology treatment, but also raises concerns about patient safety and healthcare equity. Tune in for the latest updates and insights.

21 mrt 2025 - 5 min
aflevering New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer artwork

New Approvals in Oncology: Vimseltinib for TGCT, Sotorasib for KRAS G12C CRC, and Immunotherapy in ER Positive Breast Cancer

Love what you hear? Download the Curie app from the App Store today [https://curie.md/app.html?utm_source=podcastplatforms&utm_medium=social&utm_campaign=normal&utm_term=doctors&utm_content=podcast]. Curie is your personalized, expert-driven healthcare podcast platform—offering in-depth analysis, timely insights, and discussions tailored for medical professionals. In this episode of Curie, Matt covers three major updates in oncology. Vimseltinib (Romvimza) has been FDA-approved for tenosynovial giant cell tumors (TGCT), providing a new non-surgical option for symptomatic patients. Sotorasib plus panitumumab is now approved for KRAS G12C-mutated colorectal cancer, marking a breakthrough in targeted therapy for this hard-to-treat population. Finally, two phase III trials show that adding immunotherapy to neoadjuvant chemotherapy improves pathological complete response rates in high risk ER positive, HER2 negative breast cancer—a potential paradigm shift in treatment. Tune in for the latest updates in precision oncology!

21 mrt 2025 - 5 min
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Makkelijk in gebruik!
App ziet er mooi uit, navigatie is even wennen maar overzichtelijk.

Kies je abonnement

Meest populair

Tijdelijke aanbieding

Premium

20 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

2 maanden voor € 1
Daarna € 9,99 / maand

Begin hier

Premium Plus

Onbeperkt luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 7 dagen gratis
Daarna € 13,99 / maand

Probeer gratis

Alleen bij Podimo

Populaire luisterboeken

Veelgestelde vragen

Meer vragen & antwoorden
Begin hier

2 maanden voor € 1. Daarna € 9,99 / maand. Elk moment opzegbaar.